186 related articles for article (PubMed ID: 23471415)
21. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
Lu ZX; Liu LT; Qi XR
Int J Nanomedicine; 2011; 6():1661-73. PubMed ID: 21904456
[TBL] [Abstract][Full Text] [Related]
22. Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance.
Merkel OM; Beyerle A; Librizzi D; Pfestroff A; Behr TM; Sproat B; Barth PJ; Kissel T
Mol Pharm; 2009; 6(4):1246-60. PubMed ID: 19606864
[TBL] [Abstract][Full Text] [Related]
23. Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model.
Ho EA; Osooly M; Strutt D; Masin D; Yang Y; Yan H; Bally M
J Pharm Sci; 2013 Jan; 102(1):227-36. PubMed ID: 23132529
[TBL] [Abstract][Full Text] [Related]
24. Chemically defined polyethylene glycol siRNA conjugates with enhanced gene silencing effect.
Gaziova Z; Baumann V; Winkler AM; Winkler J
Bioorg Med Chem; 2014 Apr; 22(7):2320-6. PubMed ID: 24613624
[TBL] [Abstract][Full Text] [Related]
25. PEGylation rate influences peptide-based nanoparticles mediated siRNA delivery in vitro and in vivo.
Aldrian G; Vaissière A; Konate K; Seisel Q; Vivès E; Fernandez F; Viguier V; Genevois C; Couillaud F; Démèné H; Aggad D; Covinhes A; Barrère-Lemaire S; Deshayes S; Boisguerin P
J Control Release; 2017 Jun; 256():79-91. PubMed ID: 28411182
[TBL] [Abstract][Full Text] [Related]
26. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice.
Gao S; Dagnaes-Hansen F; Nielsen EJ; Wengel J; Besenbacher F; Howard KA; Kjems J
Mol Ther; 2009 Jul; 17(7):1225-33. PubMed ID: 19401674
[TBL] [Abstract][Full Text] [Related]
27. Development of an MRI-visible nonviral vector for siRNA delivery targeting gastric cancer.
Chen Y; Wang W; Lian G; Qian C; Wang L; Zeng L; Liao C; Liang B; Huang B; Huang K; Shuai X
Int J Nanomedicine; 2012; 7():359-68. PubMed ID: 22848158
[TBL] [Abstract][Full Text] [Related]
28. Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production.
Tagami T; Nakamura K; Shimizu T; Ishida T; Kiwada H
J Control Release; 2009 Aug; 137(3):234-40. PubMed ID: 19361546
[TBL] [Abstract][Full Text] [Related]
29. Effect of polymer structure on micelles formed between siRNA and cationic block copolymer comprising thiols and amidines.
Christie RJ; Miyata K; Matsumoto Y; Nomoto T; Menasco D; Lai TC; Pennisi M; Osada K; Fukushima S; Nishiyama N; Yamasaki Y; Kataoka K
Biomacromolecules; 2011 Sep; 12(9):3174-85. PubMed ID: 21863796
[TBL] [Abstract][Full Text] [Related]
30. In Vitro and In Vivo Tumor-Targeting siRNA Delivery Using Folate-PEG-appended Dendrimer (G4)/α-Cyclodextrin Conjugates.
Ohyama A; Higashi T; Motoyama K; Arima H
Bioconjug Chem; 2016 Mar; 27(3):521-32. PubMed ID: 26715308
[TBL] [Abstract][Full Text] [Related]
31. Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide.
Lee SH; Kim SH; Park TG
Biochem Biophys Res Commun; 2007 Jun; 357(2):511-6. PubMed ID: 17434451
[TBL] [Abstract][Full Text] [Related]
32. Multifunctional siRNA delivery system: polyelectrolyte complex micelles of six-arm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide.
Choi SW; Lee SH; Mok H; Park TG
Biotechnol Prog; 2010; 26(1):57-63. PubMed ID: 19918765
[TBL] [Abstract][Full Text] [Related]
33. In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier.
Naeye B; Deschout H; Caveliers V; Descamps B; Braeckmans K; Vanhove C; Demeester J; Lahoutte T; De Smedt SC; Raemdonck K
Biomaterials; 2013 Mar; 34(9):2350-8. PubMed ID: 23261216
[TBL] [Abstract][Full Text] [Related]
34. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
35. PEGylation of biodegradable dextran nanogels for siRNA delivery.
Naeye B; Raemdonck K; Remaut K; Sproat B; Demeester J; De Smedt SC
Eur J Pharm Sci; 2010 Jul; 40(4):342-51. PubMed ID: 20435139
[TBL] [Abstract][Full Text] [Related]
36. Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes.
Hattori Y; Machida Y; Honda M; Takeuchi N; Yoshiike Y; Ohno H; Onishi H
J Liposome Res; 2017 Dec; 27(4):264-273. PubMed ID: 27345333
[TBL] [Abstract][Full Text] [Related]
37. Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes.
Mao S; Neu M; Germershaus O; Merkel O; Sitterberg J; Bakowsky U; Kissel T
Bioconjug Chem; 2006; 17(5):1209-18. PubMed ID: 16984130
[TBL] [Abstract][Full Text] [Related]
38. Balancing cationic and hydrophobic content of PEGylated siRNA polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo.
Nelson CE; Kintzing JR; Hanna A; Shannon JM; Gupta MK; Duvall CL
ACS Nano; 2013 Oct; 7(10):8870-80. PubMed ID: 24041122
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the physicochemical properties and the biocompatibility of polyethylene glycol-conjugated gold nanoparticles: A formulation strategy for siRNA delivery.
Rahme K; Guo J; Holmes JD; O'Driscoll CM
Colloids Surf B Biointerfaces; 2015 Nov; 135():604-612. PubMed ID: 26322474
[TBL] [Abstract][Full Text] [Related]
40. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection.
Lipka J; Semmler-Behnke M; Sperling RA; Wenk A; Takenaka S; Schleh C; Kissel T; Parak WJ; Kreyling WG
Biomaterials; 2010 Sep; 31(25):6574-81. PubMed ID: 20542560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
